FOXA2 and cancer: These observations lead us to propose that the synergism between Foxa2 and PI3K pathway activation in endometrial and other cancers is a consequence of their impact on distinct biological processes of cell cycle progression and EMT that are critical for the acquisition of invasive and metastatic phenotypes.